NEUROMETRIX to be acquired by ELECTROCORE

Summary

Electrocore (NASDAQ: ECOR) has reached a definitive agreement to acquire NeuroMetrix (NASDAQ: NURO), including its Quell platform. ECOR will purchase all outstanding shares of NURO for an amount equivalent to NURO’s net cash balance at the time of transaction completion, less appropriate fees.+ 2

Impact Analysis

The acquisition of NeuroMetrix by Electrocore represents a strategic move at the company level. This event could potentially impact both companies in several ways:

• Direct Impact (First-Order Effects):

• Electrocore (ECOR): The acquisition allows Electrocore to expand its product portfolio by incorporating NeuroMetrix’s Quell platform, which could enhance Electrocore’s market presence in pain management technology.

• NeuroMetrix (NURO): Shareholders will be directly affected as they will receive cash equivalent to the company’s net cash balance, potentially providing immediate liquidity or a minor premium depending on the net cash position.

• Indirect Impact (Second-Order Effects):

• This acquisition could prompt competitors to reassess their strategies in the neurotechnology and pain management sectors, potentially leading to further consolidation or strategic alliances.

• The integration of technologies might lead to increased efficiency and innovation, potentially setting industry trends in the long-term.

• Investment Opportunities:

• Investors might consider Electrocore’s stock as potentially undervalued if the acquisition leads to substantial growth in revenues and market share.

• Monitoring NeuroMetrix’s stock prior to transaction completion could reveal opportunities for arbitrage or short-term trading based on the acquisition news.

Risks to consider include the execution risk of integrating NeuroMetrix’s operations into Electrocore and potential regulatory hurdles that could affect the transaction timeline.+ 2